Cargando…

Cardiovascular Outcome Studies With Novel Antidiabetes Agents: Scientific and Operational Considerations

Detalles Bibliográficos
Autores principales:	Hirshberg, Boaz, Katz, Arie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2013
Materias:	The Heart in Diabetes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920790/ https://www.ncbi.nlm.nih.gov/pubmed/23882054 http://dx.doi.org/10.2337/dcS13-2041

Ejemplares similares

Impact of the U.S. Food and Drug Administration Cardiovascular Assessment Requirements on the Development of Novel Antidiabetes Drugs
por: Hirshberg, Boaz, et al.
Publicado: (2011)

The Case for: Hypoglycemia Is of Cardiovascular Importance
por: Lalic, Nebojsa M.
Publicado: (2013)

Cardiovascular Importance of Hyperglycemia and Hypoglycemia
por: Tkáč, Ivan
Publicado: (2013)

Is Glucose Control Important for Prevention of Cardiovascular Disease in Diabetes?
por: Mannucci, Edoardo, et al.
Publicado: (2013)

Glycemic Variability: Both Sides of the Story
por: Ceriello, Antonio, et al.
Publicado: (2013)

Cardiovascular morbidity and mortality in patients with type 2 diabetes using novel antidiabetic medicines as add-on therapy: an observational real-world study
por: Zerovnik, Spela, et al.
Publicado: (2021)

Cardiovascular mortality and oral antidiabetic drugs: protocol for a systematic review and network meta-analysis
por: Goyat, Rashmi, et al.
Publicado: (2017)

Emerging Evidence for the Use of Antidiabetic Drugs, Glucagon-like Peptide 1 Receptor Agonists, for the Treatment of Alzheimer’s Disease
por: Colin, Ides M, et al.
Publicado: (2023)

Scientific and Regulatory Considerations for the Approval of the First Generic Glucagon
por: Pang, Eric, et al.
Publicado: (2021)

Novel Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease: What Cardiologists and Diabetologists Should Know
por: Martínez, Felipe
Publicado: (2021)

How Do We Continue Treatment in Patients With Type 2 Diabetes When Therapeutic Goals Are Not Reached With Oral Antidiabetes Agents and Lifestyle? Incretin versus insulin treatment
por: Gallwitz, Baptist, et al.
Publicado: (2013)

Biochemical Basis of the Antidiabetic Activity of Oleanolic Acid and Related Pentacyclic Triterpenes
por: Castellano, Jose M., et al.
Publicado: (2013)

Changing use of antidiabetic drugs in the UK: trends in prescribing 2000–2017
por: Wilkinson, Samantha, et al.
Publicado: (2018)

The Problem of Schizophrenia and Social Class
por: Arie, Thomas
Publicado: (1966)

Honey - A Novel Antidiabetic Agent
por: Erejuwa, Omotayo O., et al.
Publicado: (2012)

Optimal diet for cardiovascular and planetary health
por: Verschuren, W M Monique, et al.
Publicado: (2022)

Assessment and management of cardiovascular disease in the intensive care unit
por: Cook, David Jonathan, et al.
Publicado: (2022)

Empagliflozin and Cardio-renal Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease – Implications for Clinical Practice
por: Fitchett, David H
Publicado: (2018)

Use of multiple antidiabetic medications in patients with diabetes and its association with hypoglycaemic events: a case-crossover study in Jordan
por: Naser, Abdallah Y, et al.
Publicado: (2018)

Cardiovascular outcomes and safety with antidiabetic drugs
por: Aldossari, Khaled K.
Publicado: (2018)

Novel Cardiovascular Biomarkers Associated with Increased Cardiovascular Risk in Women With Prior Preeclampsia/HELLP Syndrome: A Narrative Review
por: Bovee, Esmee ME, et al.
Publicado: (2021)

Imaging as a surrogate marker of drug efficacy in cardiovascular disease
por: Tarkin, Jason M, et al.
Publicado: (2019)

Sex differences in cardiovascular outcome during progression of aortic valve stenosis
por: Cramariuc, Dana, et al.
Publicado: (2015)

AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases
por: Lu, Qingguo, et al.
Publicado: (2019)

The Anti-Inflammatory Effect of Novel Antidiabetic Agents
por: Theofilis, Panagiotis, et al.
Publicado: (2022)

Effects of protocol-based management on the post-operative outcome after systemic to pulmonary shunt
por: Ismail, Sameh R., et al.
Publicado: (2018)

Effect of cardiac rehabilitation on cardiovascular risk factors in chronic heart failure patients
por: Mohammed, Haitham Galal, et al.
Publicado: (2018)

Cardiovascular disease risk in immune-mediated inflammatory diseases: recommendations for clinical practice
por: Agca, Rabia, et al.
Publicado: (2022)

Proinflammatory Protein CARD9 Is Essential for Infiltration of Monocytic Fibroblast Precursors and Cardiac Fibrosis Caused by Angiotensin II Infusion
por: Ren, Jingyuan, et al.
Publicado: (2011)

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation
por: Tuttle, Katherine R., et al.
Publicado: (2021)

Novel Antidiabetic Agents and Their Effects on Lipid Profile: A Single Shot for Several Cardiovascular Targets
por: Piccirillo, Francesco, et al.
Publicado: (2023)

Potential antidiabetic effect of ethanolic and aqueous-ethanolic extracts of Ricinus communis leaves on streptozotocin-induced diabetes in rats
por: Gad-Elkareem, Mohamed A.M., et al.
Publicado: (2019)

Normalization of HbA1c Following an Ad-Libitum, Non-Ketogenic Low Carbohydrate Diet Along With Antidiabetic Agents
por: Torbay, Naji, et al.
Publicado: (2021)

Glycaemic control efficacy of oral antidiabetic drugs in treating type 2 diabetes: a protocol for network meta-analysis
por: Jia, Yongliang, et al.
Publicado: (2015)

Comparative cardiovascular outcomes of novel drugs as an addition to conventional triple therapy for heart failure with reduced ejection fraction (HFrEF): a network meta-analysis of randomised controlled trials
por: Suebsaicharoen, Thanakit, et al.
Publicado: (2023)

A qualitative improvement program for minimally invasive mitral surgery: technical advancements ameliorate outcome and operative times
por: Gollmann-Tepeköylü, Can, et al.
Publicado: (2023)

Periodontitis is an independent risk indicator for atherosclerotic cardiovascular diseases among 60 174 participants in a large dental school in the Netherlands
por: Beukers, Nicky G F M, et al.
Publicado: (2017)

Antidiabetic and antiosteoporotic pharmacotherapies for prevention and treatment of type 2 diabetes-induced bone disease: protocol for two network meta-analyses
por: Deng, Jiawen, et al.
Publicado: (2020)

Meta‐analysed numbers needed to treat of novel antidiabetic drugs for cardiovascular outcomes
por: Wolff, Georg, et al.
Publicado: (2022)

A novel neurotensin/xenin fusion peptide enhances β-cell function and exhibits antidiabetic efficacy in high-fat fed mice
por: Perry, Rachele A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gvhev88r3r9hth9ra3hsr7dnkq